|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Accounts receivable net of allowance for credit losses of $5,448 and $828, respectively | ||||||||||||||||||||
| Other receivables | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Derivative asset | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Land held for sale | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, plant, and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use asset | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Deferred tax assets | ||||||||||||||||||||
| Other long-term assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Operating lease liabilities, current | ||||||||||||||||||||
| Deferred income | ||||||||||||||||||||
| Notes payable, short-term | ||||||||||||||||||||
| Convertible notes, net of issuance costs | ||||||||||||||||||||
| Other liabilities, current | ||||||||||||||||||||
| Derivative liability | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Earnout liability | ||||||||||||||||||||
| Canadian Government Research and Development Program liability | ||||||||||||||||||||
| Assumed common stock warrants liability | ||||||||||||||||||||
| Common stock warrants liability | ||||||||||||||||||||
| Notes payable, long-term | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Other liabilities, long-term | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2026 and December 31, 2025 | ||||||||||||||||||||
| Common stock, $0.0001 par value, 1,000,000,000 shares authorized; 5,499,307 and 5,173,884, issued and outstanding as of March 31, 2026 and December 31, 2025, respectively (including 50,000 and 50,000, respectively, of Sponsor Vesting Shares) | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
| Sponsor vesting shares issued (in shares) | ||||||||||||||||||||
Loading...
